Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Chuck Woolery, game show host of ‘Love Connection’ and ‘Scrabble,’ dies at 83
The affable, smooth-talking game show host of "Wheel of Fortune," "Love Connection" and "Scrabble" later became a right-wing podcaster.
2 Dartmouth fraternity members and a sorority have been charged in death of a student
The Alpha Phi sorority and two members of Beta Alpha Omega have been charged after a student was found dead in a river after attending an off-campus party where alcohol was allegedly served to minors.
A new installation lets you hear extinct and endangered animal sounds, thanks to Björk
The Icelandic pop star Björk's new installation at Centre Pompidou in Paris uses animal sounds to help people understand what's lost and what we stand to lose as a result of human-caused climate change.
Fold paper. Insert lens. This $2 microscope changes how kids see the world
The Foldscope brings a powerful science tool to schools that can't afford microscopes. Scientists use it too. Its creators have handed out 2 million units, including a new mini-model for younger kids.
Israeli strike kills Lebanese soldier as Hezbollah fires rockets at Israel
An Israeli strike on a Lebanese army center on Sunday killed one soldier and wounded 18 others, the Lebanese military said.
Jimmy O. Yang opens up about one of his deepest fears
Actor Jimmy O. Yang is learning how to take compliments. On Wild Card this week, he opens up about love languages and fears.
